ArticleDigestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society2025
Verification in an animal study of the appropriate settings for a novel radiofrequency generator in radiofrequency ablation therapy for residual intraductal lesions after endoscopic papillectomy (with video).
Article in Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endoscopic intraductal radiofrequency ablation (ID-RFA) can curatively treat residual intraductal lesions after endoscopic papillectomy. This study aimed to verify the tissue invasiveness of ID-RFA using a novel RF generator and to explore its appropriate settings in an animal experiment, followed by a small clinical study. Pig liver specimens were ablated using a dedicated RF catheter and two RF generators to investigate structural differences between them and the ablation effects produced under various voltage and power settings. Appropriate settings for the novel generator were sought to provide an ablation effect equivalent to that with the recommended settings for a conventional generator. The ablation effect was also observed at various ablation times in vitro. Then we performed ID-RFA in five patients. Each generator has a different structure, and no novel generator settings are identical to the recommended conventional generator settings. Obtaining adequate ablation requires both sufficient power and sufficient voltage. Based on the validation experiments, we concluded that the appropriate novel generator settings were 125 Vp and 30 W for 30 s. In the clinical study, good tumor ablation was obtained with no recurrence after a single ID-RFA treatment, although the incidence of ductal stricture was relatively high. ID-RFA for residual intraductal lesions may potentially be curative. However, excessive ablation should be avoided. To ensure safe and effective ID-RFA, a thorough understanding of the RF generator specifications is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.